PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩50 per share · Prices as of the 2026-10-02 close
Jinbiotech is showing a recovery in profitability from its animal feed additive and veterinary medicine business, while a second-largest shareholder's declared intent to influence management and a shareholder proposal have added a governance dimension to the story.
Consolidated 2025 revenue reached KRW 90.79 billion with operating profit of KRW 3.92 billion, extending a recovery from prior years.
Over the trailing four quarters (Q3 2025 to Q2 2026), net income attributable to owners fluctuated quarter to quarter, rebounding to KRW 1.29 billion in Q2 2026.
Second-largest shareholder Kim Sung-ho, CEO of Renew Medical, has steadily raised his stake to around 13% by 2026 and submitted a shareholder proposal to the board calling for treasury share cancellation and an interim dividend, among other measures.
The company has a history of skipping dividends for several fiscal years, but the most recent disclosure indicates cash dividends per share have resumed.
The debt-to-equity ratio has been managed within a stable 36-41% range between 2022 and 2025.
Founded in 2000 and listed on KOSDAQ in 2006, Jinbiotech specializes in functional feed additives for livestock, developing, producing, and selling probiotics, enzyme preparations, and immune enhancers based on proprietary microbial fermentation technology.
In 2011 the company expanded into veterinary medicine by bringing Dawon Chemical, an animal drug manufacturer, under its consolidated structure. The additives segment supplies fermented protein and probiotic products such as Pepsoigen, Anerbens, and Lactocare to compound feed plants and livestock farms.
A key technical strength is cost competitiveness achieved through shortened production cycles using solid-state fermentation and by skipping purification/separation steps in enzyme manufacturing.
The portfolio also includes disinfectant products such as Speed Kill, aimed at avian influenza and African swine fever prevention.
More recently, the company has invested in new growth areas including functional additives and exclusive premix supply for the companion animal market, as well as cultured meat research and development.
Its product lineup is segmented by livestock type, covering swine, cattle, and poultry, with domestic compound feed makers and livestock farms as its main customer base.
The feed additive and veterinary medicine market features competition among numerous small and mid-sized players, where technological capability and cost competitiveness largely determine market position.
| Quarter | Revenue | Operating profit | Op. margin |
|---|---|---|---|
| 2025Q2 | ₩23.1B | ₩900M | 3.9% |
| 2025Q3 | ₩24.3B | ₩1.4B | 5.6% |
| 2025Q4 | ₩20.5B | ₩900M | 4.5% |
| 2026Q1 | ₩21.5B | ₩800M | 3.6% |
| 2026Q2 | ₩23B | ₩1.5B | 6.5% |
| Year | Revenue | Operating profit | Net income (parent) | Op. margin | ROE | Debt-to-equity |
|---|---|---|---|---|---|---|
| 2022 | ₩82.8B | ₩1.7B | ₩1.5B | 2.0% | 3.3% | 40.1% |
| 2023 | ₩79.5B | ₩4B | ₩2.6B | 5.0% | 5.4% | 36.7% |
| 2024 | ₩83B | ₩3.8B | ₩2.9B | 4.6% | 5.6% | 41.2% |
| 2025 | ₩90.8B | ₩3.9B | ₩3.8B | 4.3% | 6.9% | 37.5% |
Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-08-23
Consolidated 2025 revenue came in at KRW 90.79 billion, up from KRW 82.96 billion in 2024, with operating profit of KRW 3.92 billion representing an operating margin of 4.3%.
Notably, the operating margin edged down slightly from 5.0% in 2023 and 4.6% in 2024, indicating revenue growth did not fully translate into margin expansion.
Net income attributable to owners rose sharply to KRW 3.79 billion in 2025 from KRW 2.87 billion in 2024, a jump that outpaced the modest increase in operating profit, suggesting non-operating factors played some role.
Looking at the trailing four quarters (Q3 2025 through Q2 2026), revenue moved from KRW 24.26 billion to KRW 20.54 billion to KRW 21.50 billion to KRW 23.02 billion, showing seasonal fluctuation, while operating profit swung from KRW 1.36 billion to KRW 0.92 billion to KRW 0.76 billion to KRW 1.50 billion, underscoring notable quarter-to-quarter volatility.
In particular, net income attributable to owners in Q2 2025 (KRW 1.21 billion) exceeded that quarter's operating profit (KRW 0.90 billion), and a similar pattern of net income (KRW 1.29 billion) approaching operating profit (KRW 1.50 billion) recurred in Q2 2026, indicating non-operating items are influencing quarterly results.
The margin trajectory, having fallen to 2.0% in 2022 before recovering to a 3-5% range in 2023-2025, can be read as a sign of cost structure stabilization or product mix improvement.
On the cash generation side, operating cash flow swung between negative territory in 2022 (KRW -3.68 billion) and 2024 (KRW -0.46 billion) and strongly positive levels in 2023 (KRW 7.37 billion) and 2025 (KRW 7.61 billion), a sign-flipping pattern that suggests working capital changes such as inventory and receivables have a considerable impact on reported results.
The animal feed additive and veterinary medicine industry is a moderately growing market underpinned by rising demand for livestock productivity improvement and antibiotic replacement both domestically and globally.
As regulations on antibiotic use tighten, structural demand for eco-friendly alternatives such as probiotics and enzyme preparations is being supported.
Seasonally, demand for disinfectant products tends to concentrate in autumn and winter when livestock diseases such as avian influenza and African swine fever are more likely to occur.
The competitive landscape is a mix of numerous small and mid-sized feed additive companies and the in-house R&D arms of large feed manufacturers, with patented technology and cost competitiveness determining individual companies' market standing.
Jinbiotech is regarded as having secured technical competitiveness through production cost reduction via solid-state fermentation technology and a number of registered patents.
That said, results are linked to upstream cycles such as raw material and grain prices and fluctuations in domestic livestock headcount, meaning individual companies' cost management and new product development capabilities tend to matter more than overall industry growth.
No specific quantitative revenue or profit guidance from the company has been publicly identified.
However, continued expansion of production infrastructure and R&D output has been confirmed, including the 2025 completion of a logistics warehouse in the Nam-Gongju Industrial Complex and a patent registration related to a feed additive for reducing rumen greenhouse gas emissions.
Ahead of the winter disease-prevention season, demand for disinfectant products such as Speed Kill could fluctuate depending on the incidence of avian influenza and African swine fever, a seasonal variable to watch.
Expansion of functional additives and premix supply for the companion animal segment is cited as a new growth driver, though specific figures such as revenue contribution are not available in public disclosures.
Separately, the shareholder proposal submitted to the board in late January 2026 by second-largest shareholder Kim Sung-ho centers on full cancellation of treasury shares, establishment of internal M&A rules, introduction of an interim dividend, and enhanced disclosure; whether these items are actually placed on the agenda and pass at a general shareholders meeting is flagged as a key variable for the future direction of shareholder return policy.
Reports that Renew Medical is preparing for a KOSDAQ listing targeted for the first half of 2027 have also led to market speculation about a potential backdoor listing scenario depending on how the governance dispute unfolds.
The current share price trades below net asset value per share, placing it in a discounted range relative to book value.
As net income has shown a steady recovery trend since 2022, the price-to-earnings multiple has moved accordingly, with the recent level not appearing to be a marked departure from the trading range observed over the past several years.
On the dividend side, given the company's multi-year history of skipping payouts, the sustainability and potential expansion of the recently resumed dividend policy remains a key variable in assessing the dividend yield level going forward.
Amid the ongoing governance dispute, with the second-largest shareholder pushing for treasury share cancellation and dividend expansion, any resulting change in shareholder return policy is flagged as a factor that could affect the share price's relationship to net asset value.
However, whether these factors translate into actual policy changes depends on decisions at shareholder meetings and the board, leaving uncertainty in place for now.
PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-08-23
Operating margin has improved from a low of 2.0% in 2022 to a 3-5% range in 2023-2025, and net income attributable to owners has clearly risen from KRW 1.52 billion in 2022 to KRW 3.79 billion in 2025.
Q2 2026 also showed improvement from the prior quarter with operating profit of KRW 1.50 billion and net income of KRW 1.29 billion. Continuation of this earnings recovery could be read as a positive signal for financial stability.
The second-largest shareholder has submitted a proposal to the board covering full cancellation of treasury shares, introduction of an interim dividend, and establishment of M&A internal rules, creating pressure for a change in shareholder return policy.
Indeed, the most recent disclosure confirms cash dividends per share have resumed, indicating some shift in dividend policy is already underway. With the debt ratio stably managed in the 36-41% range, the company appears to have financial capacity to support dividend expansion or share buybacks.
As antibiotic use regulations tighten, structural demand for eco-friendly alternatives such as probiotics and enzyme preparations is being supported.
The company's disease-prevention product portfolio, including the disinfectant Speed Kill for avian influenza and African swine fever, offers potential for demand increases during seasonal disease outbreaks. Cost competitiveness based on solid-state fermentation technology is also cited as a technical strength.
The second-largest shareholder Kim Sung-ho has raised his stake to around 13% and formalized his intent to influence management, while the gap with largest shareholder Lee Chan-ho (roughly 28% including related parties) is not large, making the outcome of any vote difficult to predict.
There have been instances where a planned extraordinary general meeting was announced but not actually convened, raising the possibility the dispute could drag on. A prolonged governance dispute raises concerns about potential inconsistency in management decision-making.
Both revenue and operating profit over the trailing four quarters have repeatedly fluctuated, and in Q1 2026 in particular operating profit fell to KRW 0.76 billion, showing the earnings improvement trend has not been consistently sustained every quarter.
Operating cash flow was also negative in both 2022 and 2024, indicating persistent volatility in cash generation tied to working capital changes. This raises uncertainty in short-term earnings forecasting.
There are reports that Renew Medical, led by the second-largest shareholder, is targeting a KOSDAQ listing in the first half of 2027, and market speculation exists that the outcome of the governance dispute could lead to discussions of a backdoor listing.
However, there is also a risk that market expectations could reverse if such a scenario fails to materialize or if the synergy with the existing business proves limited. Backdoor listing-related issues could function as an event-driven variable separate from the core business fundamentals.
With no large gap in ownership between the largest and second-largest shareholders, the ongoing dispute over management control carries the risk of escalating into board reshuffling or legal proceedings such as lawsuits.
Because minority shareholder sentiment appears likely to determine the dispute's outcome, competition over proxy voting could intensify.
Fluctuations in domestic livestock headcount and grain/raw material prices directly affect revenue and cost structure. Demand for disease-prevention products can shift rapidly depending on the occurrence of livestock diseases such as avian influenza and African swine fever, adding volatility to earnings forecasts.
As a small-cap KOSDAQ stock, limited trading volume can amplify price volatility in response to news or disclosures. The possibility of sharp short-term supply-demand shifts driven by governance dispute-related news flow cannot be ruled out.
The Q3 2026 earnings disclosure should be checked to see whether the revenue and operating profit recovery trend continues and whether non-operating profit/loss volatility eases.
It is worth monitoring whether the second-largest shareholder files for an extraordinary general meeting or places agenda items before the board, and whether discussions on treasury share cancellation and an interim dividend advance.
Changes in demand for disinfectant and other disease-prevention products should be monitored in line with the incidence of avian influenza and African swine fever.
Follow-up disclosures or news regarding Renew Medical's progress toward a KOSDAQ listing (or backdoor listing) and any connection to Jinbiotech should be checked.
Jinbiotech has shown a recovery in operating margin and net income since 2022 on the back of its stable core business in feed additives and veterinary medicine, while maintaining a relatively stable financial structure with the debt ratio managed within a 36-41% range.
However, both revenue and profit have continued to fluctuate on a quarterly basis, meaning the earnings improvement has not progressed smoothly every quarter.
At the same time, second-largest shareholder Kim Sung-ho has raised his stake to around 13% while formalizing his intent to exert influence over management, and has submitted a shareholder proposal calling for treasury share cancellation and an interim dividend, among other measures, suggesting governance-related uncertainty could persist for some time.
Recent confirmation that dividends have resumed points to some sign of change in shareholder return policy, but whether this evolves into a sustained and expanded policy depends on decisions at shareholder meetings and the board.
The backdoor listing scenario tied to Renew Medical's potential listing remains an event-driven variable separate from business fundamentals. Investors will want to watch both the sustainability of the core business's earnings recovery and how the governance dispute unfolds.
Report written 2026-09-05 · Data as of 2026-09-04
This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.